| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/04/2022 | 0.83% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 164.43% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 42.68% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 234.82% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 224.36% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 231.97% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 275.73% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 187.26% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 152.07% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 127.34% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 95% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 56% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | -18.2% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | -21.05% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | -29.61% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 23.66% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 105.46% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy | |
| 05/24/2018 | 53.14% | DA Davidson | $135 → $161 | Maintains | Buy |
| 04/19/2018 | — | Sidoti & Co. | Downgrades | Buy → Neutral |
Medifast Questions & Answers
The latest price target for Medifast (NYSE: MED) was reported by DA Davidson on November 4, 2022. The analyst firm set a price target for $106.00 expecting MED to rise to within 12 months (a possible 0.83% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Medifast (NYSE: MED) was provided by DA Davidson, and Medifast downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on November 4, 2022 so you should expect the next rating to be made available sometime around November 4, 2023.
While ratings are subjective and will change, the latest Medifast (MED) rating was a downgraded with a price target of $278.00 to $106.00. The current price Medifast (MED) is trading at is $105.13, which is out of the analyst's predicted range.